Galvus

The EMA ( European Medicines Agency ) is investigating findings by a group of independent academic researchers that suggest an...


Guidelines suggest setting individualised targets for glycaemic control in elderly patients with type 2 diabetes, despite no evidence.The aim of...


The Committee for Medicinal Products for Human Use ( CHMP ) has finalised a review of GLP-1-based diabetes therapies. The...


Novartis has provided a safety update to European regulators of pooled data showing numerically less frequent liver enzyme elevations in...


Vildagliptin ( Galvus ), a new once-daily oral treatment option for type 2 diabetes, has demonstrated efficacy, especially in patients...


Research suggests that the investigational drug Vildagliptin ( Galvus ) improves the function of pancreatic islets in both animals and...